

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	IMAGION BIOSYSTEMS LIMITED
ABN	42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael HARSH
Date of last notice	14 June 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	24 June 2019
No. of securities held prior to change	<ul style="list-style-type: none"> • 150,000 Performance Rights, issued under the Company's Long Term Incentive Plan (LTI), and automatically vesting into Shares on a one-for one basis on the vesting date, being 24 months after the Company was officially quoted. • 50,000 Performance Rights, issued under the Company's Incentive Stock Option Plan (ISO), and automatically vesting into Shares on a one-for one basis on the vesting date, being 6 June 2020.
Class	i) Fully Paid Ordinary Shares (Shares) ii) Performance Rights
Number acquired	i) 150,000 Shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	ii) 150,000 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	150,000 Performance Rights were released from escrow and automatically vested on 24 June 2019. The Performance Rights then converted into Shares at nil exercise price pursuant to the conditions outlined in the Replacement Prospectus dated 21 June 2017.
No. of securities held after change	<ul style="list-style-type: none"> • 150,000 Shares • 50,000 Performance Rights, issued under the Company's ISO, and automatically vesting into Shares on a one-for one basis on the vesting date, being 6 June 2020.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights under the LTI Plan have vested, and converted into fully paid ordinary shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	IMAGION BIOSYSTEMS LIMITED
ABN	42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John HAZLE
Date of last notice	30 July 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	24 June 2019
No. of securities held prior to change	150,000 Performance Rights, issued under the Company's Long Term Incentive Plan (LTI), and automatically vesting into Shares on a one-for one basis on the vesting date, being 24 months after the Company was officially quoted.
Class	Fully Paid Ordinary Shares (Shares)
Number acquired	150,000 Shares
Number disposed	150,000 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	150,000 Performance Rights were released from escrow and automatically vested on 24 June 2019. The Performance Rights then converted into Shares at nil exercise price pursuant to the conditions outlined in the Replacement Prospectus dated 21 June 2017.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	150,000 Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights under the LTI Plan have vested, and converted into fully paid ordinary shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	IMAGION BIOSYSTEMS LIMITED
ABN	42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David LUDVIGSON
Date of last notice	14 June 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	24 June 2019
No. of securities held prior to change	<ul style="list-style-type: none"> • 150,000 Performance Rights, issued under the Company's Long Term Incentive Plan (LTI), and automatically vesting into Shares on a one-for one basis on the vesting date, being 24 months after the Company was officially quoted. • 50,000 Performance Rights, issued under the Company's Incentive Stock Option Plan (ISO), and automatically vesting into Shares on a one-for one basis on the vesting date, being 6 June 2020.
Class	i) Fully Paid Ordinary Shares (Shares) ii) Performance Rights
Number acquired	i) 150,000 Shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	ii) 150,000 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	150,000 Performance Rights were released from escrow and automatically vested on 24 June 2019. The Performance Rights then converted into Shares at nil exercise price pursuant to the conditions outlined in the Replacement Prospectus dated 21 June 2017.
No. of securities held after change	<ul style="list-style-type: none"> • 150,000 Shares • 50,000 Performance Rights, issued under the Company's ISO, and automatically vesting into Shares on a one-for one basis on the vesting date, being 6 June 2020.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights under the LTI Plan have vested, and converted into fully paid ordinary shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	IMAGION BIOSYSTEMS LIMITED
ABN	42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jovanka NAUMOSKA
Date of last notice	14 June 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	24 June 2019
No. of securities held prior to change	<ul style="list-style-type: none"> • 150,000 Performance Rights, issued under the Company's Long Term Incentive Plan (LTI), and automatically vesting into Shares on a one-for one basis on the vesting date, being 24 months after the Company was officially quoted. • 50,000 Performance Rights, issued under the Company's Incentive Stock Option Plan (ISO), and automatically vesting into Shares on a one-for one basis on the vesting date, being 6 June 2020.
Class	i) Fully Paid Ordinary Shares (Shares) ii) Performance Rights
Number acquired	i) 150,000 Shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	ii) 150,000 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	150,000 Performance Rights were released from escrow and automatically vested on 24 June 2019. The Performance Rights then converted into Shares at nil exercise price pursuant to the conditions outlined in the Replacement Prospectus dated 21 June 2017.
No. of securities held after change	<ul style="list-style-type: none"> • 150,000 Shares • 50,000 Performance Rights, issued under the Company's ISO, and automatically vesting into Shares on a one-for one basis on the vesting date, being 6 June 2020.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights under the LTI Plan have vested, and converted into fully paid ordinary shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	IMAGION BIOSYSTEMS LIMITED
ABN	42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark VAN ASTEN
Date of last notice	14 June 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	24 June 2019
No. of securities held prior to change	<ul style="list-style-type: none"> • 150,000 Performance Rights, issued under the Company's Long Term Incentive Plan (LTI), and automatically vesting into Shares on a one-for one basis on the vesting date, being 24 months after the Company was officially quoted. • 50,000 Performance Rights, issued under the Company's Incentive Stock Option Plan (ISO), and automatically vesting into Shares on a one-for one basis on the vesting date, being 6 June 2020.
Class	i) Fully Paid Ordinary Shares (Shares) ii) Performance Rights
Number acquired	i) 150,000 Shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	ii) 150,000 Performance Rights
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	150,000 Performance Rights were released from escrow and automatically vested on 24 June 2019. The Performance Rights then converted into Shares at nil exercise price pursuant to the conditions outlined in the Replacement Prospectus dated 21 June 2017.
No. of securities held after change	<ul style="list-style-type: none"> • 150,000 Shares • 50,000 Performance Rights, issued under the Company's ISO, and automatically vesting into Shares on a one-for one basis on the vesting date, being 6 June 2020.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights under the LTI Plan have vested, and converted into fully paid ordinary shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.